Accord Healthcare (Accord) is pleased to announce that patients with advanced prostate cancer now have a new treatment option as TLV has decided to support the first and only oral castration treatment for advanced hormone-sensitive prostate cancer, androgen deprivation therapy ( ADT).
the European Medicines Agency (EMA) approved the treatment of Orgovyx®, a gonadotropin-releasing hormone (GnRH) antagonist 3 . By binding to and blocking the GnRH receptor, GnRH antagonists rapidly reduce testicular testosterone production. Stopping the release of testosterone from the testicles in prostate cancer is called medical castration and is the cornerstone of medical treatment for prostate cancer. In the past, medical castration treatment was only available as a depot injection or depot implant, which could cause injection-related side effects and tie up healthcare providers' time. The most commonly used castration treatments (so-called GnRH agonists) take longer to achieve the required effect than GnRH antagonists 4 .
" We are working at Accord to develop new treatment options that meet the needs of patients and healthcare. Orgovyx is a good example of a treatment that benefits both parties, reduces side effects and makes administration easier for patients and frees up resources for the healthcare system when injections are not needed," says Jan Stenfors, Medical and Scientific Advisor For the Nordic and Baltic countries.
Anders Bjartell, professor of urology and chief physician at Skåne University Hospital in Malmo, commented on the approval of the grant: " It is great to be able to offer our patients with advanced prostate cancer a very fast-acting castration treatment in the form of a tablet. After treating patients in the HERO trial, we are now looking forward to evaluating this exciting new drug on a larger scale. "
" The TLV estimates that the effect of relugolix in lowering serum testosterone levels is significantly better than that of leuprorelin ."
" TLV estimates that the costs of using Orgovyx do not exceed the costs that TLV considers reasonable for the treatment of very serious diseases ."
" All in all, TLV assesses that the operating costs of Orgovyx are reasonable and that the criteria of Section 15 of the Benefits Act are met in other respects as well. The application must therefore be approved."
Prostate cancer is the most common type of cancer in men in Sweden and the leading cause of cancer mortality in men. There are about 10,000 new cases every year, and the median age of diagnosis is 70.5 years. Most patients who cannot be cured by surgery or radiation therapy receive castration treatment, often in addition to other medical treatments.
About Accord Healthcare
accord Healthcare is one of Europe's fastest growing pharmaceutical companies. Our global organization enables us to deliver important, affordable medicines that benefit patients worldwide.
Accord is constantly looking for ways to improve products and increase their availability to patients.
We offer more than 40 cancer drugs and our preparations have a significant number of other drugs. Several new approvals are expected in the market over the next five years. In addition to hematological and cancer supportive care, we focus on the most important tumor diseases, such as breast and prostate cancer.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!